FR3041962B1 - Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie - Google Patents

Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie

Info

Publication number
FR3041962B1
FR3041962B1 FR1559329A FR1559329A FR3041962B1 FR 3041962 B1 FR3041962 B1 FR 3041962B1 FR 1559329 A FR1559329 A FR 1559329A FR 1559329 A FR1559329 A FR 1559329A FR 3041962 B1 FR3041962 B1 FR 3041962B1
Authority
FR
France
Prior art keywords
preparation
immunoglobulins
enriched
enriching
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1559329A
Other languages
English (en)
Other versions
FR3041962A1 (fr
Inventor
Gerald Perret
Abdessatar Sami Chtourou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR1559329A priority Critical patent/FR3041962B1/fr
Priority to EP16790642.9A priority patent/EP3356399A1/fr
Priority to US15/765,383 priority patent/US20190002537A1/en
Priority to PCT/FR2016/052512 priority patent/WO2017055775A1/fr
Publication of FR3041962A1 publication Critical patent/FR3041962A1/fr
Application granted granted Critical
Publication of FR3041962B1 publication Critical patent/FR3041962B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
FR1559329A 2015-10-01 2015-10-01 Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie Expired - Fee Related FR3041962B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1559329A FR3041962B1 (fr) 2015-10-01 2015-10-01 Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie
EP16790642.9A EP3356399A1 (fr) 2015-10-01 2016-09-30 Procédé d'enrichissement d'une préparation d'immunoglobulines en immunoglobulines anti-rsv et préparation ainsi enrichie
US15/765,383 US20190002537A1 (en) 2015-10-01 2016-09-30 Method for enriching a preparation of immunoglobulins with anti rsv immunoglobulins and preparation enriched in this way
PCT/FR2016/052512 WO2017055775A1 (fr) 2015-10-01 2016-09-30 Procédé d'enrichissement d'une préparation d'immunoglobulines en immunoglobulines anti-rsv et préparation ainsi enrichie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1559329A FR3041962B1 (fr) 2015-10-01 2015-10-01 Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie

Publications (2)

Publication Number Publication Date
FR3041962A1 FR3041962A1 (fr) 2017-04-07
FR3041962B1 true FR3041962B1 (fr) 2018-01-05

Family

ID=55022566

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1559329A Expired - Fee Related FR3041962B1 (fr) 2015-10-01 2015-10-01 Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie

Country Status (4)

Country Link
US (1) US20190002537A1 (fr)
EP (1) EP3356399A1 (fr)
FR (1) FR3041962B1 (fr)
WO (1) WO2017055775A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200246449A1 (en) * 2017-05-03 2020-08-06 Nanobio Corporation Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same
EP3873517A4 (fr) * 2018-10-29 2022-09-28 Emory University Particules de type virus rsv et leurs procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112851766A (zh) * 2013-03-13 2021-05-28 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途

Also Published As

Publication number Publication date
WO2017055775A1 (fr) 2017-04-06
US20190002537A1 (en) 2019-01-03
FR3041962A1 (fr) 2017-04-07
EP3356399A1 (fr) 2018-08-08

Similar Documents

Publication Publication Date Title
IL304842A (en) Human antibodies with improved affinity to fcrh5 - and methods of use
MA42302A (fr) Lactames bicycliques et leurs méthodes d'utilisation
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
IL248392A0 (en) Human antibodies to Middle East respiratory syndrome coronavirus spike protein
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
IL259452A (en) System and method for presentation of content linked comments
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
IL256487B (en) Methods and devices for preparing enriched biological fluids
MA41375A (fr) Anticorps igg bispécifiques et leurs procédés de préparation
DK3253412T3 (da) Anti-cd40l-antistoffer og fremgangsmåder til behandling af cd40l-forbundne sygdomme eller forstyrrelser
DK3504360T3 (da) Fremgangsmåder til behandling af vandige sammensætninger omfattende litiumsulfat og svovlsyre
IL265761B1 (en) Tralipressin compounds for oral use for the treatment of ascites
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
DK2964185T3 (da) Præparater til behandlingen af søvnrelaterede luftvejslidelser
IL269641A (en) Preparations and methods for the treatment of complications and disorders related to Factor One and Liebrand
FR3041962B1 (fr) Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie
FR3003353B1 (fr) Nouvelle methode de dosage en flux d'un objet d'interet
FR3003874B1 (fr) Procede d'enrichissement en proteines de la biomasse de microalgues
FI20155958A (fi) Maidon mineraalikoostumuksen muokkaaminen
FR3031860B1 (fr) Procede de diffusion d'un contenu multimedia protege
DK3405207T3 (da) Sammensætning med afgiftende virkning til oral indgivelse og fremgangsmåde til fremstilling deraf

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Search report ready

Effective date: 20170407

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20210605